178 related articles for article (PubMed ID: 36671744)
1. Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models.
Dilli Batcha JS; Raju AP; Matcha S; Raj S EA; Udupa KS; Gota V; Mallayasamy S
Biology (Basel); 2022 Dec; 12(1):. PubMed ID: 36671744
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
3. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L; Joerger M; Wicha SG; Ter Heine R; Csajka C; Parra-Guillen ZP; Kloft C
Clin Pharmacokinet; 2018 Feb; 57(2):229-242. PubMed ID: 28540639
[TBL] [Abstract][Full Text] [Related]
4. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Thomas L; Raju AP; Chaithra ; M SS; Varma M; Saravu K; Banerjee M; Sv CS; Mallayasamy S; Rao M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1535-1553. PubMed ID: 35852584
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
Bai Y; Wu HW; Zhang YH
Cancer Chemother Pharmacol; 2019 Jan; 83(1):71-79. PubMed ID: 30357449
[TBL] [Abstract][Full Text] [Related]
6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
ter Heine R; Binkhorst L; de Graan AJ; de Bruijn P; Beijnen JH; Mathijssen RH; Huitema AD
Br J Clin Pharmacol; 2014 Sep; 78(3):572-86. PubMed ID: 24697814
[TBL] [Abstract][Full Text] [Related]
8. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen.
Klopp-Schulze L; Mueller-Schoell A; Neven P; Koolen SLW; Mathijssen RHJ; Joerger M; Kloft C
Front Pharmacol; 2020; 11():283. PubMed ID: 32296331
[TBL] [Abstract][Full Text] [Related]
9. Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Dohollou N; Bernard-Marty C; Laharie-Mineur H; Filleron T; Roché H; Chatelut E; Thomas F; White-Koning M
Clin Pharmacol Ther; 2021 May; 109(5):1244-1255. PubMed ID: 33047329
[TBL] [Abstract][Full Text] [Related]
10. Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.
de Vries Schultink AH; Zwart W; Linn SC; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2015 Aug; 54(8):797-810. PubMed ID: 25940823
[TBL] [Abstract][Full Text] [Related]
11. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
[TBL] [Abstract][Full Text] [Related]
12.
Ahmed JH; Makonnen E; Fotoohi A; Aseffa A; Howe R; Aklillu E
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31547390
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Thompson AM; Johnson A; Quinlan P; Hillman G; Fontecha M; Bray SE; Purdie CA; Jordan LB; Ferraldeschi R; Latif A; Hadfield KD; Clarke RB; Ashcroft L; Evans DG; Howell A; Nikoloff M; Lawrence J; Newman WG
Breast Cancer Res Treat; 2011 Jan; 125(1):279-87. PubMed ID: 20809362
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer.
Zafra-Ceres M; de Haro T; Farez-Vidal E; Blancas I; Bandres F; de Dueñas EM; Ochoa-Aranda E; Gomez-Capilla JA; Gomez-Llorente C
Int J Med Sci; 2013; 10(7):932-7. PubMed ID: 23781139
[TBL] [Abstract][Full Text] [Related]
16. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.
Dickschen K; Willmann S; Thelen K; Lippert J; Hempel G; Eissing T
Front Pharmacol; 2012; 3():92. PubMed ID: 22661948
[TBL] [Abstract][Full Text] [Related]
18. Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB; de Andrade JM; Marques MP; Coelho EB; Suarez-Kurtz G; Lanchote VL
BMC Pharmacol Toxicol; 2019 Dec; 20(Suppl 1):81. PubMed ID: 31852530
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
Braal CL; Westenberg JD; Buijs SM; Abrams S; Mulder TAM; van Schaik RHN; Koolen SLW; Jager A; Mathijssen RHJ
Breast Cancer Res Treat; 2022 Aug; 195(1):65-74. PubMed ID: 35842520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
